Mendelson Daniel Newman
Known title: DirectorCIK: 0001327897
Mendelson Daniel Newman's purchase track record
How the stock did after each of Mendelson Daniel Newman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 6 since September 19, 2023
Stock higher 6 months later
17%
3 months: 17%
Median 6-month return
-17.0%
3 months: -10.4%
Beat the S&P 500
0%
median -36.8% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/11/2024 | CSBR | $19K | -20.8% | -19.5% | +16.8% |
| 1/3/2024 | CSBR | $77K | -18.5% | -21.1% | +17.7% |
| 12/19/2023 | CSBR | $46K | +11.8% | +7.7% | +15.1% |
| 10/5/2023 | CSBR | $62K | -1.6% | -19.8% | +20.9% |
| 9/27/2023 | CSBR | $112K | -8.3% | -14.5% | +22.8% |
| 9/19/2023 | CSBR | $125K | -12.5% | -2.1% | +16.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CSBR | ▲ Buy | Open Market | 1,000 | $7K | 1/12/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,000 | $13K | 1/11/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,944 | $19K | 1/10/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 3,000 | $19K | 1/9/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 1,000 | $6K | 1/8/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,000 | $12K | 1/5/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 3,000 | $18K | 1/4/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 500 | $3K | 1/3/2024 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,500 | $12K | 12/21/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,100 | $10K | 12/20/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $24K | 12/19/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $32K | 10/11/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 1,100 | $7K | 10/10/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 1,530 | $10K | 10/6/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,000 | $13K | 10/5/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $32K | 10/4/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 2,500 | $16K | 10/3/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 4,000 | $25K | 9/29/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $31K | 9/28/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 1,500 | $9K | 9/27/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $28K | 9/26/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 3,812 | $21K | 9/22/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $28K | 9/21/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 4,018 | $22K | 9/20/2023 | View on chart |
| CSBR | ▲ Buy | Open Market | 5,000 | $26K | 9/19/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Champions Oncology Highlighted in Global PDX Models Shift
Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.
Champions Oncology Highlighted in Global PDX Models Shift. Champions Oncology was highlighted in a Yahoo article that discusses the shift toward patient‑derived xenograft (PDX) models in precision oncology. The story compares the company with peers like Charles River, Crown Bioscience, The Jackson Laboratory and Oncodesign, indicating growing industry focus on PDX‑based research. This comparison suggests Champions may benefit from increased demand for its precision oncology solutions. No new financial data were disclosed.